Agentix Corp. (AGTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00848A1034
Agentix Corp. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Operating income | -513,251.00 USD | -445,187.00 USD |
| EBIT | -524,379.00 USD | -405,530.00 USD |
| Net income | -567,048.00 USD | -485,636.00 USD |
| Diluted EPS – continuing operations | -0.01 USD | -0.01 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Agentix Corp.
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
More stocks
- Aphoenity International Holdings Inc. (LDSN)
- Greentech Innovations, Inc. (GTIC)
- IP STRATEGY HOLDINGS, INC. (IPST)
- CONECTISYS CORP (CONC)
- Leader Capital Holdings Corp. (LCHD)
- ACTELIS NETWORKS INC (ASNS)
- PMGC Holdings Inc. (ELAB)
- ESCALON MEDICAL CORP (ESMC)
- Dalrada Technology Group, Inc. (DHTI)
- MORGAN GROUP HOLDING CO (MGHL)
- P2 Solar, Inc. (PTOS)
- MedWellAI, Inc. (MWAI)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.